Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an update.
Livzon Pharmaceutical Group Inc. has received clinical trial approval from the National Medical Products Administration for JP-1366, a new potassium-competitive acid blocker for injection. This approval allows the company to proceed with trials targeting peptic ulcer bleeding, further extending its research on JP-1366, which is already undergoing trials for reflux esophagitis. This step is expected to enhance Livzon’s industry positioning by expanding its portfolio of gastrointestinal treatments.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating innovative drug solutions, including injections and tablets, with a market focus on addressing gastrointestinal disorders.
YTD Price Performance: -4.35%
Average Trading Volume: 3,997
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $4.03B
For an in-depth examination of 1513 stock, go to TipRanks’ Stock Analysis page.
